Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387605 | 1.00 | MAPT (0.53) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| Hydrochloric Acid SCHEMBL2341695 | 0.98 | MAPT (0.51) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| SCHEMBL29875363 | 0.91 | PRKCZ (0.50) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| SCHEMBL11144191 | 0.91 | PRKCZ (0.50) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| SCHEMBL23557738 | 0.81 | CHUK (0.47) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| SCHEMBL22490163 | 0.79 | HIPK2 (0.53) | MAPTCYP1A2CYP2A6ACHECHUK | |
| SCHEMBL25625877 | 0.79 | CHUK (0.46) | MAPTCYP1A2CYP2A6CYP19A1ACHE | |
| SCHEMBL21415736 | 0.79 | CYP11B2 (0.53) | CYP19A1PIK3CAROCK2PRKCZCYP11B2 | |
| SCHEMBL18201498 | 0.79 | ROCK2 (0.52) | MAPTCYP1A2ROCK2IMPDH2ROCK1 | |
| SCHEMBL6562601 | 0.77 | CYP1A2 (0.77) | CYP1A2CYP2A6BACE1L3MBTL1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805204-B | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2023-09-15 | — | — | CN | claimed |
| CN-115055128-A | Preparation method of cyclopropyl-substituted nitrogen-containing six-membered heterocyclic compound | 北京六合宁远医药科技股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| CN-122055343-A | Deuterium and aryl amine compounds and uses thereof | 泽农医药公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12528774-B2 | Thiosemicarbazone compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| WO-2005046712-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | MAPT 1757/4885CYP1A2 1653/4885CYP2A6 1400/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | MAPT 3604/4885CYP1A2 4415/4885CYP2A6 3387/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | MAPT 3604/4885CYP1A2 4415/4885CYP2A6 3387/4885 |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | MAPT 4730/4885CYP1A2 439/4885CYP2A6 1519/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | MAPT 4730/4885CYP1A2 439/4885CYP2A6 1519/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | MAPT 4318/4885CYP1A2 2722/4885CYP2A6 2940/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | MAPT 3501/4885CYP1A2 2753/4885CYP2A6 1929/4885 |
| US-12528774-B2 | Thiosemicarbazone compounds and uses thereof | SCN2B, SCN1B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPT 3717/4885CYP1A2 648/4885CYP2A6 898/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | MAPT 4730/4885CYP1A2 439/4885CYP2A6 1519/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | MAPT 4314/4885CYP1A2 138/4885CYP2A6 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.